Met Life Investment Management, LLC Design Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 19,334 shares of DSGN stock, worth $94,929. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,334
Previous 19,334
-0.0%
Holding current value
$94,929
Previous $104,000
14.42%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding DSGN
# of Institutions
97Shares Held
32.1MCall Options Held
4.6KPut Options Held
2.6K-
Sr One Capital Management, LP6.53MShares$32 Million14.99% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$20.7 Million3.42% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$11.3 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$9.59 Million0.72% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.86MShares$9.12 Million0.03% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $274M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...